<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="50">
  <stage>Registered</stage>
  <submitdate>21/07/2005</submitdate>
  <approvaldate>12/08/2005</approvaldate>
  <actrnumber>ACTRN12605000133639</actrnumber>
  <trial_identification>
    <studytitle>The effect of heparin on lung function following cardiopulmonary bypass.</studytitle>
    <scientifictitle>The effect of heparin on alveolar dead space following cardiopulmonary bypass.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Lung injury following cardiac surgery.</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A double blind randomised trial comparing intravenous heparin versus placebo (5% glucose).  The infusion will be commenced 8 - 10 hours prior to commencement of surgery and ceased prior to the insertion of lines or sternotomy.</interventions>
    <comparator>Placebo (5% glucose)</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Alveolar dead space</outcome>
      <timepoint>Over the first 4 hours following cardiopulmonary bypass.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma levels of prothrombin fragments, t.PA, D. dimer</outcome>
      <timepoint>Over the first 4 hours following cardiopulmonary bypass.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult patients undergong elective cardiac surgery for coronary artery bypass grafting with cardiopulmonary bypass.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous adverse reaction to heparin. Active bleeding.  An additional surgical procedure to coronary artery bypass grafting planned.  Creatinine &gt;200umol/L.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The study drug is prepared by an independent nurse in our unit. This person is not involved in the conduct, administration or data collection for the study.  The infusion bag  is labelled 'study drug' and the patient's study number but identifies that it may be either heparin or placebo (in accordance with our hospitals drug labelling policy).  Participants are numbered sequentially and there is a central list to tell the nurse which number and associated infusion to prepare.</concealment>
    <sequence>Random number generator or odd and even numbers in blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>30/11/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype />
    <primarysponsorname>Nil</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Intensive Care Foundation and St Vincent's Hospital Melbourne ICU Research Fund</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Barry Dixon</name>
      <address>Intensive Care Unit
St Vincent's Hospital Melbourne
PO Box 2900
Fitzroy VIC 3065</address>
      <phone>+61 3 92884488</phone>
      <fax>+61 3 92884487</fax>
      <email>Barry.Dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Barry Dixon</name>
      <address>Intensive Care Unit
St Vincent's Hospital Melbourne
PO Box 2900
Fitzroy VIC 3065</address>
      <phone>+61 3 9288 488</phone>
      <fax>+61 3 92884487</fax>
      <email>Barry.Dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>